SCHEMBL4413055

SCHEMBL4413055

NC(=O)Cn1c(=O)oc2c(Br)cccc21

nearest known ligand 0.60

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.60
▸ ASAH1 Q13510 1/20 0.44
▸ MAPK1 P28482 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4419212 0.82 HPGD (0.52) HPGDMAPK1SMN1; SMN2
SCHEMBL4414547 0.82 HPGD (0.60) HPGDMAPK1SMN1; SMN2
SCHEMBL4417498 0.82 HPGD (0.60) HPGDMAPK1SMN1; SMN2
SCHEMBL4415859 0.80 HPGD (0.50) HPGDMAPK1SMN1; SMN2
SCHEMBL4416201 0.80 HPGD (0.50) HPGDMAPK1SMN1; SMN2
SCHEMBL4416694 0.79 HPGD (0.56) HPGDSMN1; SMN2
SCHEMBL4411792 0.77 HPGD (0.50) HPGDMAPK1SMN1; SMN2
SCHEMBL5427489 0.77 TSPO (0.52) —
SCHEMBL4414345 0.75 HPGD (1.00) HPGDMAPK1SMN1; SMN2
SCHEMBL4415842 0.73 HPGD (0.52) HPGDMAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1756071-B1 BENZOXAZOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB PHARMA SA (BE) 2009-08-26 — — EP claimed
US-20070299118-A1 Benzoxazolone Derivatives, Processes For Preparing Them And Their Uses UCB, S.A. (BE) 2007-12-27 — — US claimed
EP-1756071-A1 BENZOXAZOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2007-02-28 — — EP claimed
WO-2005118561-A1 BENZOXAZOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2005-12-15 — — WO claimed
US-8293775-B2 Benzoxazolone derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2012-10-23 — — US disclosed
EP-1756071-B1 BENZOXAZOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB PHARMA SA (BE) 2009-08-26 — — EP disclosed
US-20070299118-A1 Benzoxazolone Derivatives, Processes For Preparing Them And Their Uses UCB, S.A. (BE) 2007-12-27 — — US disclosed
EP-1756071-A1 BENZOXAZOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2007-02-28 — — EP disclosed
WO-2005118561-A1 BENZOXAZOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2005-12-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299118-A1 Benzoxazolone Derivatives, Processes For Preparing Them And Their Uses PARK7, SNCA, GABRA5 HPGD 232/4885ASAH1 2881/4885MAPK1 3250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback